Credit Industriel ET Commercial bought a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 609,855 shares of the biotechnology company's stock, valued at approximately $4,537,000. Grifols makes up about 0.6% of Credit Industriel ET Commercial's portfolio, making the stock its 22nd biggest position. Credit Industriel ET Commercial owned 0.09% of Grifols at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in GRFS. Cigogne Management SA acquired a new position in shares of Grifols in the fourth quarter valued at approximately $1,778,000. Syon Capital LLC acquired a new position in Grifols in the fourth quarter valued at approximately $197,000. Stifel Financial Corp boosted its stake in Grifols by 5.5% during the fourth quarter. Stifel Financial Corp now owns 123,878 shares of the biotechnology company's stock worth $922,000 after acquiring an additional 6,417 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares in the last quarter. Finally, Capital World Investors grew its stake in Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after acquiring an additional 154,358 shares during the period.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on GRFS. Morgan Stanley started coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company. Wall Street Zen raised Grifols from a "hold" rating to a "buy" rating in a report on Friday.
Check Out Our Latest Research Report on GRFS
Grifols Stock Performance
Shares of NASDAQ:GRFS traded up $0.12 during midday trading on Tuesday, reaching $8.23. The company had a trading volume of 714,892 shares, compared to its average volume of 1,159,439. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company's 50 day moving average price is $7.31 and its 200 day moving average price is $7.57. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The stock has a market cap of $5.66 billion, a P/E ratio of 7.03 and a beta of 0.44.
About Grifols
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Stories

Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.